Literature DB >> 2144026

National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project.

S K Schwarcz1, J M Zenilman, D Schnell, J S Knapp, E W Hook, S Thompson, F N Judson, K K Holmes.   

Abstract

The Gonococcal Isolate Surveillance Project is a national sentinel surveillance system to estimate levels and monitor trends of antimicrobial resistance in prospectively collected isolates of Neisseria gonorrhoeae. Of 6204 isolates evaluated from 21 clinic sites between September 1987 and December 1988, 21% met at least one of the surveillance criteria for resistance to penicillin, tetracycline, cefoxitin, or spectinomycin; 2.2% were penicillinase-producing N gonorrhoeae; 1.0% had high-level plasmid-mediated tetracycline resistance; and 16.8% of the isolates without plasmid-mediated resistance had chromosomally mediated resistance (defined as a minimum inhibitory concentration greater than or equal to 2 micrograms/mL) to penicillin, tetracycline, or cefoxitin. Three isolates were resistant to spectinomycin. All isolates were susceptible to ceftriaxone. Resistant isolates were identified from all participating centers. Patient demographic and behavioral characteristics were not predictive of infections caused by resistant organisms. These results demonstrate the wide distribution of antimicrobial-resistant N gonorrhoeae and support recent changes in Centers for Disease Control therapy recommendations for gonococcal infections that no longer recommend tetracycline and penicillin as first-line therapies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144026

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  47 in total

1.  Susceptibility of gonococci isolated in London to therapeutic antibiotics: establishment of a London surveillance programme. London Gonococcal Working Group.

Authors:  C A Ison; I M Martin
Journal:  Sex Transm Infect       Date:  1999-04       Impact factor: 3.519

2.  In vitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines.

Authors:  T E Clendennen; C S Hames; E S Kees; F C Price; W J Rueppel; A B Andrada; G E Espinosa; G Kabrerra; F S Wignall
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 3.  A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned.

Authors:  Edward W Hook; Robert D Kirkcaldy
Journal:  Clin Infect Dis       Date:  2018-09-28       Impact factor: 9.079

4.  Strain typing and antimicrobial resistance of fluoroquinolone-resistant Neisseria gonorrhoeae causing a California infection outbreak.

Authors:  Sheldon R Morris; Douglas F Moore; Paul B Hannah; Susan A Wang; Julia Wolfe; David L Trees; Gail Bolan; Heidi M Bauer
Journal:  J Clin Microbiol       Date:  2009-07-22       Impact factor: 5.948

5.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

6.  Prevalence of fluorescent monoclonal antibody-nonreactive Neisseria gonorrhoeae in five North American sexually transmitted disease clinics.

Authors:  K R Smith; H C Fisher; E W Hook
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

7.  Surveillance of antibiotic resistance in Neisseria gonorrhoeae in The Netherlands, 1977-95.

Authors:  M J van de Laar; Y T van Duynhoven; M Dessens; M van Santen; B van Klingeren
Journal:  Genitourin Med       Date:  1997-12

Review 8.  Antimicrobial agents and gonorrhoea: therapeutic choice, resistance and susceptibility testing.

Authors:  C A Ison
Journal:  Genitourin Med       Date:  1996-08

Review 9.  Antibiotic treatment of gonorrhoea--clinical evidence for choice.

Authors:  C Bignell
Journal:  Genitourin Med       Date:  1996-10

10.  Antimicrobial susceptibilities of Neisseria gonorrhoeae strains isolated in Surabaya, Indonesia.

Authors:  M R Joesoef; J S Knapp; A Idajadi; M Linnan; Y Barakbah; A Kamboji; P O'Hanley; J S Moran
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.